Mobile BSL3 Containerized Laboratories for Medical, Biological, DVI, Clinical, CSR and Analytical with BioSafety Level 1, 2, 3 for Hi-Risk Viruses, like COVID-19 Coronavirus, EBOLA , SARS, MERS, TB, Hepatitis, HIV/AIDS, A-H1N1 Swine Flu, H5N1 AVIAN Flu/Bird Flu and other Agents, with ORSAIR N95 3ply Masks available in quantity.

MLEE-3500 and MLEE-4000DC





| BioSafety Level 2+ | Specifications | Performance | |Integration | Communications | Other Platforms | Meteo Interfacing

ORLANDO Systems LLC , NY, specializing in the manufacturing of "Mobile Medical, Biological, Clinical and Analytical Laboratories and Health Clinics" (like this Mercedes based unit on the top or the Trailer below) for Rapid Interventions in Emergency Epidemiological situations in infected zones. ORLANDO offers equipment, design and installation from its Office and Factory locations in Hungary, Italy and USA since 1995. Started by Mr.Theo Basch, President, as Orlando Systems Inc, NY, we also markets hi-tech products, services and equipment for Radiation detection and evaluation, armoured vehicles, security systems and telecommunications.

Both Models In STOCK Now!


Mobile Biological Clinical and Analytical Laboratories BioSafety Level 2+

The original 2001 Mobile Biological Labs project was developed and manufactured by Orlando Systems Inc/Orlando Telecom Srl in Bucharest , in collaboration with Romanian companies, Military and Health Organizations, incorporating US, EU and local technologies.

The primary mission of our Bio-Safety LEVEL 2+ & BSL3 Labs entails Mobile response in Emergency Medical Situations, in support of Medical Teams. Also CSR, Communicable diseases Surveillance and Response, as GATHERING AND CONSERVATION OF SAMPLES, monitoring and verification, diagnosis/Rapid Testing, for severe epidemics or BIOTERROR alarms, oriented towards the presented dangers (MERS, COVID-19 Coronavirus, EBOLA, SARS, Swine Flu, AVIAN Flu, ANTHRAX, Variola, Botullin, Cholera, TBC, Malaria, Legionaries, Hepatitis, etc). Optionally other NBC equipment can be incorporated. For Veterinarian applications, BSL2+ and BSL3, please visit our site

The Labs are profiled as Peripheral-Intermediary, as per WHO standards, for Intervention in Infected Epidemical and Pandemic areas for H1N1, H5N1, COVID-19 Coronavirus, EBOLA, SARS, AIDS, Ebola (under special BSl conditions), Small Pox and are therefore being offered for medical care in Africa/Asia. Very difficult medical situations like Afghanistan or Iraq are typical as well as the Asian Tsunami affected areas and Earthquake disaster areas. EU Road testing has been completed, RAR homologated as Trailer and Truck based integrated units with projects in Africa and Asia.

The basic mission proposed for this containerized Mobile BSL2+ and BSL3 Lab is to be transported or self - transported in a very short time anywhere there is a Medical Emergency with possible Infections, and Epidemic Emergency , BIOTERROR alarm or a Bio danger has to be verified (just like the H1N1, Bird Flu or the COVID-19 Coronavirus, EBOLA, SARS situation) including sea or airborne applications. It can be located close to the source of the infection and works as a RULE+REFFER instrument, without additional risk of further propagation via unnecessary (according to the latest CDC Atlanta strategies).

The Labs are built in custom cut-away containerized Aluminum CLEAN ROOM trailers and can be integrated with Commercial Truck Chassis like Transit/Mercedes Sprinter, FORD, Iveco, and other type chassis vehicles as self-supporting 4 wheel platforms. We also expect integration with boats and pontoons for water transport use.

Technical Specifications
1. The technology used in the ORLANDO Mobile Medical Labs MLEE-3500DC, MLEE-4000DC, MLEE-4000Trailer, MLBSL2-3500 (with 2,000 - 3,000 kg gross weight and 3 - 4 meters long) is modular, user oriented, and easy to use. These models, ready for Bio Threat-A, are equipped with Level 2+ and BSL3 protection, via its Bio-Safety Level II Laminar Flow units and other special features like an optional sample entry compartment, and used for collecting, Rapid Test, Rule+Refer as per CDC-Atlanta and WHO recommended rules. The labs also include an externally attached 2x3x3meter weatherproof tent, for decontamination and sample collection, with easy access to power, decontamination equipment and optionally a number of protection uniforms, masks, oxygen, and vaccines. The MLEE-3500DC, the MLEE-4000DC, the MLBSL-3500 and others are upgraded to Biosafety Levels 2+ and BSL3.

2. The Lab container can be easily pressurized with fresh air if needed, at a Low Negative level by its fully integrated double Bio HEPA filtration system (in and out air flow). The project will have a Civil WHO level homologation for Health Sanitation, Civil and Military Defense. The Lab container respects the WHO recommendations for Peripheral Labs and has 1 or 2 medical refrigerators/freezers plus its own Autoclave unit. Equipped with a performant A/C system, it has a programmable internal power grid of 220VAC & 12VC, a Power Generator with over 15 hours of independence, several hours of back-up from batteries and a 220V inverter/converter with a set of Marine Solar Cells included.

3. The Mobile Lab MLEE-3500 in one of its many versions (as mounted on a 4 wheel trailer platform with air suspension and mounted on a Mercedes Sprinter Turbo Diesel DOKA 411) has passed the RAR organization road test, according to the European norms for 2,000kg and 4,500kg and is legally licensed in EU. The USA Made FORDS MLEE-4000DC, are Export Models, built for ME and Asia.

4. The Mobile Support integration or transport unit will be supplied and modified locally in end-user country whenever possible (land/water). We have used Mercedes and FORD so far and some other standard and off-road 4 wheel-drive vehicles of similar weight and as possible candidates for this job.

5. The Mobile Labs have built in Wifi Hotspots for active connections between Computers, Tablets, Smartphones and Instruments. The Optional VHF/Tetra/GSM, Inmarsat, Intelsat or 3,5GHz communication modules, etc, can be integrated in the system (custom design) for voice/data on the internally provided platform, with 220VCA or 12 VDC supply and antenna outlets.

6. Training for these Mobile Labs with modern diagnostics technologies (PCR, Chemical/ ELISA) wil be offered in collaboration with Your local Infectious diseases center. Biological testing was done for HEPA integrity on the BSL2 units.

Other Platforms
7. We are presently preparing plans for other Mobile Laboratory platforms, tropicalised, applicable for Vaccination, Veterinarian campaigns, Nuclear accidents, for Airborne & Seaborne needs. Also supplied in co-operation with other partners are planned units for clinical, high level telecommunication, goniometry, aircraft, EPA-pollution, based on modular systems, with 2-3 integrated remotes.

Meteo Interfacing
8. The ORLANDO manufactured BSL2+ and BSL3 Mobile Medical Laboratories can be optionally equipped with a modern digital station for Meteorology and Pollution detection: radioactivity, chemical and industrial gases (Gammalert) for accidents or radioactive material attacks. Meteo and Pollution Monitoring Station support is built-in, with pre-wiring in place.





Other ORLANDO Systems LLC sites: and

Email: and



Copyright © 2005-2021, Orlando Systems LLC and KFT, All Rights Reserved.

Our ORSAIR PhoenixDX 2019-NCOV is a real-time RT-PCR-based detection system for the 2019 Wuhan coronavirus (2019-nCoV). 2019-nCoV is considered a novel human coronavirus that is genetically distinct from the common human coronaviruses (229E, NL63, OC43, HKU1), which cause seasonal acute respiratory illness. It is also genetically distinct from the two newer human coronaviruses, MERS-CoV and SARS-CoV.

Our Test Kit (50 tests) ORSAIR PhoenixDX 2019-NCOV detects the presence of 3 different and highly specific gene sequences of 2019-nCoV: E gene, N gene and RdRP gene. All 3 assays must be tested positive to confirm the sample as 2019-nCoV-positive.

Additionally, a non-infectious positive control and a negative human extraction control are included. The positive control is used to confirm functionality of the assays and overall PCR performance, the negative human extraction control is included to evaluate the quality of the RNA isolation independently from the 2019-nCoV assays.

The first step in the detection of 2019-nCoV is the conversion of viral RNA into cDNA. Afterwards, the target sequences unique for 2019-nCoV are specifically amplified with amplification monitored in real time through the use of fluorescently labelled probes: upon incorporation into the newly amplified DNA strands, the fluorophore (FAMTM) is released and an increase in fluorescence signal can be observed. Due to the intrinsic mutation rate of coronaviruses, it is possible that mutations in the target sequence occur and accumulate over time. This can lead to false-negative results with a PCR- based detection approach.

ORSAIR PhoenixDX 2019-NCOV addresses this issue by using 3 detection assays on 3 different target sequences to minimize the chance of false-negative results caused by an altered target sequence. If samples are tested negative in one or more assays, additional complementary testing may be required. The original target sequences for 2019-nCoV are included as a non-infectious target positive control (TPC) to check the integrity of the detection assays.

Samples tested positive should always be confirmed through complementary methods and additional analysis in an independent laboratory.


Specimens can be stored at 4°C for up to 72 hours after collection.

If a delay in extraction is expected, store specimens at -70°C or lower. Extracted nucleic acids should be stored at -70°C or lower. Do not use specimens if: they were not kept at 2-4°C (≤ 4 days) or frozen at -70°C or below. they are insufficiently labelled or lack documentation. they are not suitable for this purpose (see above for suitable sample material). the specimen volume is insufficient.


The performance of RT-PCR assays strongly depends on the amount and quality of sample template RNA. It is strongly recommended to qualify and validate RNA extraction procedures for recovery and purity before testing specimens.

Suitable nucleic acid extraction systems successfully used in combination with ORSAIR PhoenixDX DETECTION KITS include: bioMérieux NucliSens® systems, QIAamp® Viral RNA Mini Kit, QIAamp® MinElute Virus Spin Kit or RNeasy® Mini Kit (QIAGEN), EZ1 DSP Virus Kit (QIAGEN), Roche MagNA Pure Compact RNA Isolation Kit, Roche MagNA Pure Compact Nucleic Acid Isolation Kit, and Roche MagNA Pure 96 DNA and Viral NA Small Volume Kit, and Invitrogen ChargeSwitch® Total RNA Cell Kit. Store and keep residual specimens and extracted nucleic acids at -70°C.

Only thaw the number of specimen extracts that will be tested in a single day. Do not freeze/thaw extracts more than once before testing as each freeze/thaw cycle will decrease the RNA quality. It may be possible to use patient samples directly, depending on the sample type. However, this may require a prior lysis step and titration of the amount on sample that can be used without inhibiting the reaction. This procedure has not been validated, use of isolated RNA is recommended.

Please email for more information and a ask QUOTE = always indicate if you are a End-User or not and WHICH MODEL of PCR are your using?

Mr.Theo BASCH,